Methods for Producing Retinal Pigment Epithelium Cells
Summary
The USPTO has published a new patent application detailing methods for producing retinal pigment epithelium (RPE) cells. The application describes specific culturing and replating techniques using laminin substrates to expand and mature RPE cells for potential therapeutic uses.
What changed
This document is a patent application (US20260085285A1) filed by the USPTO, outlining novel methods for producing retinal pigment epithelium (RPE) cells. The described methods involve culturing human pluripotent stem cells on specific laminin substrates (LN-521, LN-511, LN-111, or LN-121) for a defined period, dissociating them, replating them on a second laminin substrate, and further culturing to achieve expanded and matured RPE cells. The application also covers RPE cells produced by these methods and their use in various treatments.
While this is a patent application and not a regulatory rule, it signifies a new development in biotechnology and potential therapeutic applications. Companies involved in regenerative medicine, cell therapy, or ophthalmic treatments should be aware of this patented technology. Compliance officers in the pharmaceutical and medical device sectors should monitor the progress of this patent and similar innovations, as they may influence future product development, intellectual property strategies, and market entry for RPE-based therapies.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR PRODUCING RETINAL PIGMENT EPITHELIUM CELLS
Application US20260085285A1 Kind: A1 Mar 26, 2026
Inventors
Karl Anders Fredrik Lanner, Álvaro Plaza Reyes, Sandra Petrus Reurer, Sara Padrell Sánchez
Abstract
Methods comprise exposing a culture of human pluripotent stem cells adherent on a first substrate comprising a first laminin to a differentiation medium for a first time period of 15 days to 50 days to obtain a first population of adherent cells comprising RPE cells and/or progenitors thereof; at the end of the first time period, dissociating the first population from the first substrate; replating the dissociated first population of cells on a second substrate comprising a second laminin; and culturing the replated first population of cells on the second substrate for a second time period to obtain an expanded and matured second population of cells comprising the RPE cells. The first and second laminins are independently selected from LN-521, LN-511, LN-111 and LN-121, and are an intact protein or protein fragment. Also included are RPE cells and materials and compositions utilizing such RPE cells for various treatments.
CPC Classifications
C12N 5/0621 C12N 2500/98 C12N 2501/115 C12N 2501/15 C12N 2501/16 C12N 2533/52
Filing Date
2025-12-04
Application No.
19408516
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.